The EU pharmaceutical package aims to accelerate life sciences industries growth and promote sustainable healthcare systems for European patients. Patient access, market access, availability disparities, supply shortages, and supply chain and innovation challenges drive review and reform of the EU pharmaceutical legislation—the foundation of pharmaceutical industry manufacturing of safe, effective, high quality medicinal products in Malta and European countries.
In Malta’s healthcare sector, the pricing and reimbursement strategies for medicinal products and medical devices reflect a distinct dual-market system. The public sector, driven by principles of social solidarity, offers patients access to essential medications free of charge, selected from a government-regulated formulary.
Medicine, Healthcare, Pharmacy, and the law Journal of the Malta College of Pharmacy Practice http://www.mcppnet.org/publications/issue18-11.pdf By, Anthia Zammit LL.B, LL.D… read more →
Times of Malta, 30th September 2010 , by Dr Anthia Zammit : Launched in December 2008, the ambitious package is intended to… read more →